APA (7th ed.) Citation

C, B., S, O., M, T., R, K., S, S., R, T., . . . M, K. (2023). The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 44(6), 2121. https://doi.org/10.1007/s10072-023-06608-z

Chicago Style (17th ed.) Citation

C, Boz, et al. "The Comparative Effectiveness of Fingolimod, Natalizumab, and Ocrelizumab in Relapsing-remitting Multiple Sclerosis." Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 44, no. 6 (2023): 2121. https://doi.org/10.1007/s10072-023-06608-z.

MLA (9th ed.) Citation

C, Boz, et al. "The Comparative Effectiveness of Fingolimod, Natalizumab, and Ocrelizumab in Relapsing-remitting Multiple Sclerosis." Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, vol. 44, no. 6, 2023, p. 2121, https://doi.org/10.1007/s10072-023-06608-z.